Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
Tel: 650-421-8100
Website: http://www.codexis.com/
About Codexis, Inc.
Codexis is a leading enzyme engineering company leveraging our proprietary CodeEvolver® technology platform to discover and develop novel, high performance enzymes for three healthcare industry pillars: pharmaceutical manufacturing, life sciences, and biotherapeutic discovery & development. The enzymes we produce aim to solve real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and - as biotherapeutic candidates - they have the potential to treat challenging diseases. To meet this goal, we look for individuals who are driven, eager to grow and ready to embrace meaningful challenges. We empower employees to be authentic, ambitious, agile and have the courage to take action where they can make a positive impact. Whether you are driven by science, or a different area of expertise, we need you to help us create a brighter future.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
86 articles about Codexis, Inc.
-
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
11/3/2021
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, announced today the dosing of the first subject in a Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108.
-
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
9/9/2021
Codexis, Inc. announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient in Merck’s JANUVIA® and one of the active ingredients in Merck’s JANUMET®.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences in September 2021
9/7/2021
Codexis, inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in two upcoming virtual investment conferences.
-
Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company
8/25/2021
Codexis, Inc. announced the Company received new purchase orders with an aggregate total value of approximately $15 million for the 2021 supply of a proprietary high performance enzyme used to manufacture a critical intermediate for an Active Pharmaceutical Ingredient in a therapeutic drug for an undisclosed global pharmaceutical company.
-
Codexis Reports Second Quarter 2021 Financial Results
8/5/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the second quarter ended June 30, 2021 and provided a business update.
-
Codexis to Report Second Quarter 2021 Financial Results on August 5
7/22/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that it will report its financial results for the second quarter of 2021 on Thursday, August 5, 2021, following the close of market.
-
Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader
7/14/2021
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver® platform technology transfer with Novartis Pharma AG (“Novartis”) today.
-
Codexis Earns Milestone Payment from GlaxoSmithKline
7/7/2021
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK).
-
Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product
6/17/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company.
-
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
-
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
6/10/2021
Codexis, Inc. announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences
5/25/2021
Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences.
-
Codexis to Participate in Upcoming Virtual Healthcare Conferences - May 17, 2021
5/17/2021
Codexis, Inc., a leading enzyme engineering company, announced that management will participate in three upcoming virtual investment conferences.
-
Codexis Reports First Quarter 2021 Financial Results
5/6/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the first quarter ended March 31, 2021 and provided a business update.
-
Codexis to Report First Quarter 2021 Financial Results on May 6
4/22/2021
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2021 on Thursday, May 6, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
-
Codexis Reports Fourth Quarter and Fiscal Year 2020 Financial Results
2/25/2021
Strong Product Revenue Momentum in Second Half of 2020 Drives Company’s Seventh Consecutive Year of YOY Revenue Growth
-
Codexis to Present at Upcoming Virtual Healthcare Conferences
2/18/2021
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences.
-
Codexis to Report Fourth Quarter and Full Year 2020 Results on February 25
2/11/2021
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
-
Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth
2/9/2021
Codexis, Inc., a leading enzyme engineering company, announced it will be expanding its operations into a new 36,000 square foot facility in San Carlos, CA under a ten year lease.
-
Codexis Appoints Dr. Esther Martinborough to its Board of Directors
2/3/2021
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.